RORγt Inhibitor Small Molecules for Autoimmune Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases and inflammation related to RORγt activity are inadequate in effectively inhibiting RORγt, leading to insufficient regulation of Th17 cell differentiation and IL-17 production.
Innovation Solution
Development of specific small molecule compounds with RORγt inhibitory activity, which are used in pharmaceutical compositions to treat cancer, inflammation, and autoimmune diseases by targeting RORγt, thereby regulating immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune diseases and inflammation are used, then treatment is provided, but RORγt inhibition is insufficient leading to inadequate regulation of Th17 cell differentiation and IL-17 production
Solution Approach 1:
The patent applies parameter changes by developing small molecule compounds with specific chemical structures (Formula I, II, III, IV, V) that optimize binding affinity to RORγt. The compounds feature variable substituents (R groups, Z positions, Linker L1/L2) that can be tuned to enhance inhibitory potency, directly addressing the insufficient RORγt inhibition of current treatments
Solution Approach 2:
The patent employs composite molecular structures combining heterocyclic rings (pyridine, pyrimidine, triazine), aromatic systems, and flexible linkers in specific configurations. These composite structural elements work synergistically to achieve potent and selective RORγt inhibition, overcoming the limitations of existing single-structure treatments
2Reliability
If specific small molecule compounds with RORγt inhibitory activity are developed, then effective treatment options are provided, but the complexity of identifying compounds with both strong inhibitory activity and good pharmacokinetic characteristics increases
Solution Approach 1:
The patent segments the RORγt ligand-binding domain interaction into distinct structural modules: core heterocyclic systems (A/B rings), substituent groups (R0-R9), and linker regions (L1/L2). This segmentation allows systematic optimization of each module's contribution to binding affinity and pharmacokinetic properties, reducing the complexity of identifying effective compounds
Solution Approach 2:
The patent systematically varies key molecular parameters including molecular weight, logP, hydrogen bond donors/acceptors, and polar surface area within the compound structures. These parameter optimizations balance potent RORγt inhibition with favorable pharmacokinetic characteristics, streamlining the compound development process
Data Source
AI summary
A RORγt inhibitor as well as a preparation method thereof and uses thereof, and a pharmaceutical composition including the compound, a method for preparing the pharmaceutical composition, and use of the compound or the pharmaceutical composition in the treatment or prevention of RORγt-mediated cancer, inflammation, or autoimmune diseases in mammals, especially humans.